Search

Displaying results 4121 - 4130 of 4235 in total
  1. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).

  2. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  3. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    Tofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site...

  4. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its impr...

  5. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  6. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  7. Drug

    TY027

    go.drugbank.com/drugs/DB16500
    Investigational

  8. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    The synthetic version of this peptide has been manufactured and covalently linked to iodine 131 as a means of targeting radiation to tumor cells in the treatment of brain cancer.

  9. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    As of August, 2020 the candidate is in Phase II clinical trials[A219758].

  10. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment